At a glance
ClinicalIndex Comparison RecordN/ACompleted· 16 enrolled
Drug / intervention
calcitriol +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Oral Calcitriol in Patients at High Risk for Lung Cancer
In Brief
A clinical study evaluating calcitriol, laboratory biomarker analysis, and 1 other intervention for Lung Cancer and 2 related conditions. Completed, enrolled 16 participants across 1 site.
Detailed Summary
RATIONALE: Calcitriol may prevent lung cancer in patients with metaplasia or dysplasia of the lungs. PURPOSE: This clinical trial is studying the side effects and best dose of calcitriol in preventing lung cancer in current smokers and former smokers at high risk of lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Precancerous Condition, Tobacco Use Disorder
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJul 2008
Primary CompletionMar 2017
Study CompletionMar 2018
TodayJul 2026
First PostedJun 5, 2008
Enrollment StartJul 17, 2008
Primary CompletionMar 7, 2017
Study CompletionMar 7, 2018
TodayJul 2, 2026
Enrollment to primary: 8.6 yearsPosted 18.1 years ago
Interventions
calcitrioldrug
Oral
laboratory biomarker analysisother
Correlative Study
pharmacological studyother
Correlative Study